Biotech Values

[biomaven0]

I can't say I can argue with GS's determination

Now I think everyone here knows I am now (and have in the past also been) much more cautious on MNTA than say Dew. But this GS report is, to steal a famous phrase, not even wrong. It's one thing to differ from the MNTA bull case on the prospects for Teva generic lovenox and for a generic copaxone, but it's quite another thing to say:

other companies will be unable to gain approvals of generic Lovenox in the near-term (as they lack Momenta’s proprietary technology)

and

We believe the probability is high that Momenta (again partnered with Novartis) receive FDA approval of M356, its generic version of Teva’s Copaxone.

and then to come up with a price target of $15. That's just incoherent.

Peter